KALA BIO Q3 net loss $9.0M; cash $49.2M; Phase 2b topline due 2Q 2025

KALA BIO, Inc.

2024-Q3 EPS reported -$8.68

Net loss $9.0M ($1.93/share) in Q3 2024 vs $8.7M ($3.41) in Q3 2023.
Cash $49.2M as of Sep 30, 2024; funding expected into Q4 2025; includes $3.2M from CIRM.
R&D $5.2M, G&A $4.4M; operating loss $10.0M in Q3 2024.
Phase 2b CHASE trial for PCED enrolling; topline data expected 2Q 2025; five sites in Argentina.
Exploring KPI-012 for LSCD (est. 100k patients); preclinical KPI-014 for inherited retinal diseases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.